RS51519B - HYINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF PERIPHERAL ARTERIAL DISEASES AND AS PHOSPHODIESTERASE INHIBITORS - Google Patents
HYINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF PERIPHERAL ARTERIAL DISEASES AND AS PHOSPHODIESTERASE INHIBITORSInfo
- Publication number
- RS51519B RS51519B RSP-2010/0523A RSP20100523A RS51519B RS 51519 B RS51519 B RS 51519B RS P20100523 A RSP20100523 A RS P20100523A RS 51519 B RS51519 B RS 51519B
- Authority
- RS
- Serbia
- Prior art keywords
- treatment
- peripheral arterial
- arterial disease
- phosphodiesterase inhibitors
- derivatives useful
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US59843204P | 2004-08-04 | 2004-08-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
RS51519B true RS51519B (en) | 2011-06-30 |
Family
ID=35839972
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RSP-2010/0523A RS51519B (en) | 2004-08-04 | 2005-08-04 | HYINAZOLINE DERIVATIVES USEFUL FOR TREATMENT OF PERIPHERAL ARTERIAL DISEASES AND AS PHOSPHODIESTERASE INHIBITORS |
Country Status (22)
Country | Link |
---|---|
US (1) | US20060030574A1 (zh) |
EP (2) | EP1949893B1 (zh) |
JP (1) | JP4758993B2 (zh) |
CN (1) | CN101014344A (zh) |
AT (1) | ATE484278T1 (zh) |
AU (1) | AU2005271275A1 (zh) |
BR (1) | BRPI0513943A (zh) |
CA (1) | CA2575512C (zh) |
CY (1) | CY1110881T1 (zh) |
DE (1) | DE602005024192D1 (zh) |
DK (1) | DK1949893T3 (zh) |
EA (1) | EA200700406A1 (zh) |
ES (1) | ES2353848T3 (zh) |
HR (1) | HRP20100681T1 (zh) |
MX (1) | MX2007001513A (zh) |
NO (1) | NO20071098L (zh) |
PL (1) | PL1949893T3 (zh) |
PT (1) | PT1949893E (zh) |
RS (1) | RS51519B (zh) |
SI (1) | SI1949893T1 (zh) |
WO (1) | WO2006017823A2 (zh) |
ZA (1) | ZA200701850B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001021259A2 (en) * | 1999-09-21 | 2001-03-29 | Emory University | Use and compositions for treating platelet-related disorders using anagrelide |
US8304420B2 (en) * | 2006-11-28 | 2012-11-06 | Shire Llc | Substituted quinazolines for reducing platelet count |
GB0623750D0 (en) * | 2006-11-28 | 2007-01-10 | Shire Llc | Substituted quinazolines |
US7910597B2 (en) * | 2006-11-28 | 2011-03-22 | Shire Llc | Substituted quinazolines |
GB0808967D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substitute quinazolines |
GB0808952D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
GB0808947D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substituted quinazolines |
GB0808968D0 (en) * | 2008-05-16 | 2008-06-25 | Shire Llc | Substitute quinazolines |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2732403A (en) * | 1956-01-24 | Chclj | ||
US2862966A (en) * | 1958-12-02 | archo | ||
US1947926A (en) * | 1934-02-20 | Seed grain dressings and process of | ||
US2256999A (en) * | 1939-03-08 | 1941-09-23 | Du Pont | Nitration of organic compounds |
US2469695A (en) * | 1946-02-02 | 1949-05-10 | Eastman Kodak Co | Nitroaminobenzene ester compounds |
US2608584A (en) * | 1947-03-19 | 1952-08-26 | Nopco Chem Co | Preparation of n-alkyl arylamines |
US2883435A (en) * | 1956-10-10 | 1959-04-21 | Gen Aniline & Film Corp | Purification of 1,2-dichloro-4-nitrobenzene |
US3313854A (en) * | 1961-11-20 | 1967-04-11 | Universal Oil Prod Co | Preparation of para-nitrodiphenylamines utilizing a copper oxide catalyst |
US3932407A (en) * | 1973-11-19 | 1976-01-13 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
USRE31617E (en) * | 1972-02-04 | 1984-06-26 | Bristol-Myers Company | Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones |
JPS49132019A (zh) * | 1973-02-26 | 1974-12-18 | ||
DE2400887A1 (de) * | 1974-01-09 | 1975-08-28 | Bayer Ag | Verfahren zur herstellung von nitroderivaten aromatischer verbindungen |
JPS5752352B2 (zh) * | 1974-02-28 | 1982-11-06 | ||
US3983119A (en) * | 1974-11-06 | 1976-09-28 | Bristol-Myers Company | Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones |
US3983120A (en) * | 1974-11-06 | 1976-09-28 | Bristol-Myers Company | Process for the preparation of optionally substituted 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones |
US3988340A (en) * | 1975-01-23 | 1976-10-26 | Bristol-Myers Company | 6-Alkoxymethyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones and 7-alkoxymethyl-6-[H]-1,2,3,4-tetrahydropyrimido[2,1-b]quinazolin-2-ones |
JPS5251379A (en) * | 1975-10-24 | 1977-04-25 | Sumitomo Chem Co Ltd | Preparation 3,4-dihydro-2(1h)-quinazoline derivates |
JPS5291885A (en) * | 1976-01-23 | 1977-08-02 | Sumitomo Chem Co Ltd | 3,4-dihydro-2(1h)-quinazolinone derivatives |
NL7807507A (nl) * | 1977-07-25 | 1979-01-29 | Hoffmann La Roche | Tricyclische verbindingen. |
US4146718A (en) * | 1978-04-10 | 1979-03-27 | Bristol-Myers Company | Alkyl 5,6-dichloro-3,4-dihydro-2(1h)-iminoquinazoline-3-acetate hydrohalides |
US4208521A (en) * | 1978-07-31 | 1980-06-17 | Bristol-Myers Company | Process for the preparation of imidazo[2,1-b]quinazolinones |
EP0028489B1 (en) * | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
ZW16481A1 (en) * | 1980-08-15 | 1982-03-10 | Hoffmann La Roche | Novel imidazoquinazoline derivatives |
US4357330A (en) * | 1981-07-30 | 1982-11-02 | Bristol-Myers Company | Pharmaceutical compositions |
US4444777A (en) * | 1981-07-30 | 1984-04-24 | Bristol-Myers Company | Pharmaceutical compositions of anagrelide and sulfinpyrazone |
US4455311A (en) * | 1981-08-28 | 1984-06-19 | Hoffmann-La Roche Inc. | Imidazoquinazoline derivatives which inhibit the aggregation of blood platelets, inhibit gastric secretion or have activity on the circulatory system |
JPS6028979A (ja) * | 1983-07-14 | 1985-02-14 | Dai Ichi Seiyaku Co Ltd | イミダゾキナゾリン類化合物 |
US4837239A (en) * | 1985-08-23 | 1989-06-06 | Syntex (U.S.A.) Inc. | Cardiotonic phosphodiesterase inhibitors complexed with water soluble vitamins |
US5656286A (en) * | 1988-03-04 | 1997-08-12 | Noven Pharmaceuticals, Inc. | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
US4847276A (en) * | 1988-09-06 | 1989-07-11 | Merrell Dow Pharmaceuticals Inc. | Treatment of thromobocytosis with 5-(4-chlorophenyl)-2,4-diemthyl-3H-1,2,4-triazole-3-thione |
GB8824496D0 (en) * | 1988-10-19 | 1988-11-23 | Beecham Group Plc | Process |
MX21452A (es) * | 1989-07-07 | 1994-01-31 | Ciba Geigy Ag | Preparaciones farmaceuticas que se administran en forma topica. |
US5043327A (en) * | 1989-07-18 | 1991-08-27 | Janssen Pharmaceutica N.V. | Positive inotropic and lusitropic 3,5-dihydroimidazo[2,1-b]quinazolin-2(1H)-one derivatives, compositions and use |
US5391737A (en) * | 1991-05-22 | 1995-02-21 | Egis Gyogyszergyar | Process for the preparation of 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2[3H]-one |
US5306709A (en) * | 1991-11-15 | 1994-04-26 | The University Of Pennsylvania | Suppression of megakaryocytopoiesis by macrophage inflammatory proteins |
US6024975A (en) * | 1992-04-08 | 2000-02-15 | Americare International Diagnostics, Inc. | Method of transdermally administering high molecular weight drugs with a polymer skin enhancer |
GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
GB9423910D0 (en) | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
CA2171073A1 (en) * | 1995-12-04 | 1997-06-05 | Philip C. Lang | Process for the preparation of ethyl-n-(2,3 dichloro-6- nitrobenzyl) glycine |
AUPN814496A0 (en) * | 1996-02-19 | 1996-03-14 | Monash University | Dermal penetration enhancer |
CA2265495A1 (en) * | 1996-09-13 | 1998-03-19 | The Board Of Trustees Of The Leland Stanford Junior University | Non-hormonal method of contraception |
US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
US5874437A (en) * | 1996-11-01 | 1999-02-23 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
WO1999020223A2 (en) * | 1997-10-20 | 1999-04-29 | Novo Nordisk A/S | Luteinising hormone antagonists useful for treatment of estrogen deficiencies, or as a contraceptive |
US6548490B1 (en) * | 1997-10-28 | 2003-04-15 | Vivus, Inc. | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6156753A (en) * | 1997-10-28 | 2000-12-05 | Vivus, Inc. | Local administration of type III phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US6037346A (en) * | 1997-10-28 | 2000-03-14 | Vivus, Inc. | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction |
US20040014761A1 (en) * | 1997-10-28 | 2004-01-22 | Place Virgil A. | Treatment of female sexual dysfunction with phosphodiesterase inhibitors |
US6403597B1 (en) * | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
US6548529B1 (en) * | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
WO2001021259A2 (en) * | 1999-09-21 | 2001-03-29 | Emory University | Use and compositions for treating platelet-related disorders using anagrelide |
US6194420B1 (en) * | 1999-11-30 | 2001-02-27 | Roberts Laboratories Inc. | 2-amino-5,6-dichloro-3,4-dihydroquinazoline, its method of making and using and pharmaceutical compositions thereof |
AU3104301A (en) * | 2000-01-20 | 2001-07-31 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
US6388073B1 (en) * | 2000-07-26 | 2002-05-14 | Shire Us Inc. | Method for the manufacture of anagrelide |
US20030181461A1 (en) * | 2002-01-25 | 2003-09-25 | Lautt Wilfred Wayne | Use of phosphodiesterase antagonists to treat insulin resistance |
US20030235609A1 (en) * | 2002-01-25 | 2003-12-25 | Lautt Wilfred Wayne | Use of cholinesterase antagonists to treat insulin resistance |
US20030114673A1 (en) * | 2002-05-29 | 2003-06-19 | Lang Philip C. | 2-amino-5,6-dihalo-3,4-dihydroquinazolines with blood platelet reducing properties |
US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
KR20050111317A (ko) * | 2003-01-23 | 2005-11-24 | 샤이어 홀딩스 아게 | 혈소판혈병의 치료를 위한 제형 및 방법 |
US20060292213A1 (en) * | 2004-06-23 | 2006-12-28 | Myogen, Inc. | Enoximone formulations and their use in the treatment of PDE-III mediated diseases |
-
2005
- 2005-08-03 US US11/197,774 patent/US20060030574A1/en not_active Abandoned
- 2005-08-04 PL PL08153077T patent/PL1949893T3/pl unknown
- 2005-08-04 RS RSP-2010/0523A patent/RS51519B/en unknown
- 2005-08-04 AU AU2005271275A patent/AU2005271275A1/en not_active Abandoned
- 2005-08-04 DE DE602005024192T patent/DE602005024192D1/de active Active
- 2005-08-04 DK DK08153077.6T patent/DK1949893T3/da active
- 2005-08-04 JP JP2007525070A patent/JP4758993B2/ja not_active Expired - Fee Related
- 2005-08-04 ES ES08153077T patent/ES2353848T3/es active Active
- 2005-08-04 BR BRPI0513943-0A patent/BRPI0513943A/pt not_active IP Right Cessation
- 2005-08-04 PT PT08153077T patent/PT1949893E/pt unknown
- 2005-08-04 SI SI200531196T patent/SI1949893T1/sl unknown
- 2005-08-04 EA EA200700406A patent/EA200700406A1/ru unknown
- 2005-08-04 CA CA2575512A patent/CA2575512C/en not_active Expired - Fee Related
- 2005-08-04 AT AT08153077T patent/ATE484278T1/de active
- 2005-08-04 MX MX2007001513A patent/MX2007001513A/es unknown
- 2005-08-04 CN CNA2005800294894A patent/CN101014344A/zh active Pending
- 2005-08-04 EP EP08153077A patent/EP1949893B1/en active Active
- 2005-08-04 EP EP05784874A patent/EP1778235A4/en not_active Withdrawn
- 2005-08-04 WO PCT/US2005/028087 patent/WO2006017823A2/en active Application Filing
-
2007
- 2007-02-27 NO NO20071098A patent/NO20071098L/no not_active Application Discontinuation
- 2007-03-02 ZA ZA200701850A patent/ZA200701850B/xx unknown
-
2010
- 2010-11-09 CY CY20101101007T patent/CY1110881T1/el unknown
- 2010-12-08 HR HR20100681T patent/HRP20100681T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2006017823A3 (en) | 2006-05-04 |
CN101014344A (zh) | 2007-08-08 |
CA2575512C (en) | 2010-12-14 |
JP2008509163A (ja) | 2008-03-27 |
CA2575512A1 (en) | 2006-02-16 |
PT1949893E (pt) | 2011-01-04 |
AU2005271275A1 (en) | 2006-02-16 |
EA200700406A1 (ru) | 2007-08-31 |
EP1949893A3 (en) | 2008-08-20 |
EP1778235A2 (en) | 2007-05-02 |
EP1778235A4 (en) | 2008-08-20 |
ZA200701850B (en) | 2008-08-27 |
US20060030574A1 (en) | 2006-02-09 |
PL1949893T3 (pl) | 2011-04-29 |
DE602005024192D1 (de) | 2010-11-25 |
EP1949893B1 (en) | 2010-10-13 |
SI1949893T1 (sl) | 2011-02-28 |
MX2007001513A (es) | 2007-03-27 |
CY1110881T1 (el) | 2015-06-10 |
JP4758993B2 (ja) | 2011-08-31 |
NO20071098L (no) | 2007-05-03 |
EP1949893A2 (en) | 2008-07-30 |
ES2353848T3 (es) | 2011-03-07 |
HRP20100681T1 (hr) | 2011-01-31 |
DK1949893T3 (da) | 2011-01-31 |
WO2006017823A2 (en) | 2006-02-16 |
ATE484278T1 (de) | 2010-10-15 |
BRPI0513943A (pt) | 2008-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200701850B (en) | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | |
NO2007010I1 (no) | Sitagliptin, eventuelt i form av et farmasoytisk akseptabelt salt | |
BRPI0416628A (pt) | uso de compostos orgánicos | |
TNSN05265A1 (en) | Composition comprising a pde4 inhibitor and a pde5 inhibitor | |
AR087241A2 (es) | Derivados de 6-oh-4h-benzo[1,4]oxazin-3-ona para el tratamiento de la enfermedad pulmonar obstructiva cronica | |
EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
DE50311898D1 (de) | Fredericamycin-derivate als arzneimittel zur tumorbehandlung | |
WO2007075695A3 (en) | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of mania and bipolar disorder | |
AU5584901A (en) | Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease | |
MXPA04000793A (es) | Novedoso metodo terapeutico. | |
EA200601837A1 (ru) | Бензоксазины для лечения заболеваний дыхательных путей | |
MXPA06013039A (es) | El tratamiento de enfermedad respiratoria. | |
MXPA03011702A (es) | Composicion que comprende un inhibidor de fosodiesterasa 4 y un antagonista de receptor h1 y el uso de los mismos para la elaboracion de un medicamento para el tratamiento de enfermedades respiratorias. | |
ATE547104T1 (de) | Zusammensetzung enthaltend einen lungensurfactant und sildenafil zur behandlung von lungenerkrankungen | |
WO2007095609A3 (en) | Use of benzo-heteroaryl sulfamide derivatives for the treatment of mania and bipolar disorder | |
WO2003053352A3 (en) | Therapeutic compounds for treating dyslipidemic conditions | |
WO2004053107A3 (en) | Methods for treating diabetes | |
TW200605893A (en) | Use of organic compounds | |
DE60206391D1 (de) | Verwendung von thiazolderivaten zur herstellung eines medikaments zur behandlung von chronischen obstruktiven atemwegserkrankungen | |
UA95094C2 (ru) | Применение бензоконденсированных гетероциклических сульфамидных производных для лечения маниакального синдрома и биполярного расстройства |